C M Y CM MY CY CMY K 9 7 6 8 10 4 5 3 2 1 Co nf e r e nc e D e t a il s 8 www.lenzleberkern.com

6 th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 5-7 March 2009 Granada Spain Granada Congress & Exhibition Centre Supported by Novartis Pharmaceutical Corporation and Ipsen Beaufour

Welcome to Granada The ENETS Executive Committee extends a warm welcome to its 6th Annual Conference in Granada, Spain. In attending this meeting, you join some of the most respected and dynamic researchers and key opinion leaders in the field of neuroendocrine tumor research. Over the next two days, they will be detailing the most relevant and significant advances in the field today. Our aim is to give you beneficial lessons to help you in your daily clinical practice. On behalf of the scientific organizing committee, I welcome you to Granada. The city is a highly appropriate place to hold our conference: its legacy of blended cultures mirrors our Society s mission in fostering international cooperation toward solving the complex clinical problems neuroendocrine tumors present. The Society today claims more than 550 members, hailing from 48 countries this is a proud achievement for a research society dedicated to a rare disease, and one founded only five years ago. Again, I welcome all participants to our annual meeting and appreciate the distances traveled to be here. Our 2008 conference in Paris received very positive reviews and we hope that the Granada meeting will be just as rewarding. In inviting the conference lecturers, we hope to exhibit the Society s work of this past year, including the ENETS Guidelines for the Standards of Care. But we also felt it important to add some new aspects to the program. This would encompass poorly differentiated endocrine carcinomas, novel approaches to NET treatment, and a session on combined therapy and clinical trials. We also have expanded the program to include an additional session for clinical research abstracts. I am exceptionally proud to announce that we received 119 abstracts for the meeting. The growth in NET research, as well as the continued increase in membership registrations and abstract submissions, speaks for itself and our future work in the field. The ENETS Annual Conference this year is sponsored by the pharmaceutical firms Novartis, as platinum sponsor, and Ipsen, as silver sponsor. I would like to take this opportunity to thank both for their continued support for and interest in ENETS. I would also like to thank the companies CISBIO, Covidien, ITG Isotope Technologies Garching and Sirtex, which are exhibiting during the conference. I welcome each of you to Granada and to the ENETS 6th Annual Conference. Guido Rindi, M.D., Ph.D. Parma, Italy Chairman, European Neuroendocrine Tumor Society (ENETS) 2

Saturday, 7 March 2009 08:30-09:30 SESSION 5: Liver Metastases Chairs: D. O Toole, Dublin, IRL D. J. Kwekkeboom, Rotterdam, NED 08:30-08:50 Key Players in Metastases Development D. R. Welch, Birmingham, AL, 08:50-09:10 Surgery and Ablation T. Steinmüller, Berlin, 09:10-09:30 Medical Treatment K. Öberg, Uppsala, 09:30-10:15 SELECTED ABSTRACTS (III): Basic/Translational Research Chairs: M. Caplin, London, U.-F. Pape, Berlin, 09:30-09:45 Molecular predictors of response to chemotherapy in advanced/metastatic gastroenteropancreatic endocrine tumors A. Couvelard, Clichy, 09:45-10:00 Adenosine A2 receptor signalling mediates chromogranin A secretion from neuroendocrine tumors A. Kalhan, Cardiff, 10:00-10:15 Dual expression of alpha-internexin in pancreatic endocrine tumors and its implications M. Mei, Beijing, CHN 10:15-10:45 COFFEE BREAK 10:45-11:00 Young Investigator Awards G. Kaltsas, Athens, GRE G. Rindi, Parma, 11:00-12:30 SESSION 6: Combined Therapy and Clinical Trials Chairs: B. Kos-Kud a, Zabrze, POL M. Kulke, Boston, MA, 11:00-11:30 Hot-Off-the-Press Results of Ongoing Trials in the EU and the C. Lombard-Bohas, Lyon, J. Yao, Houston, TX, 11:30-12:00 Single or Monotherapy: Need for Combinations? L. Kvols, Tampa, FL, 12:00-12:30 Basic Evidence for Future Trials E. Van Cutsem, Leuven, BEL 12:30-12:50 Lessons from Granada R. Jensen, Bethesda, MD, 12:50-13:00 Concluding Remarks G. Rindi, Parma, END OF MEETING Mark Your Calendars Now! 7 th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumors For more information, visit: www.neuroendocrine.net 11-13 March 2010 Berlin Germany Session 5 Abstracts 3 Session 6 6th Annual ENETS Conference 7 March 2009 7

C Y CM MY CY CMY K Conference organization: Scientific organizing committee: ENETS Coordinating Office c/o Charité - University Hospital Campus Virchow-Klinikum Hepatology and Gastroenterology Augustenburger Platz 1 13353 Berlin, Germany Martyn Caplin London Wouter de Herder Rotterdam NED Barbro Eriksson Uppsala Dermot O Toole Dublin IRL tel +49 (0)30 450-553 096/-553 042 fax +49 (0)30 450-553 942 Guido Rindi Parma Philippe Ruszniewski Clichy Bertram Wiedenmann Berlin www.neuroendocrine.net office@neuroendocrine.net 4 M

Friday, 6 March 2009 08:30-10:30 SESSION 2: Various localizations, various problems Chairs: W. de Herder, Rotterdam, NED G. Delle Fave, Rome, 08:30-09:00 Lung E. Baudin, Villejuif, 09:00-09:30 Pancreas M. Mallath, Mumbai, IND 09:30-10:00 Rectum J. Ramage, Basingstoke, 10:00-10:30 Ileum F. Costa, Sao Paulo, BRA 10:30-11:00 ENETS Life Achievement Award Chair: G. Rindi, Parma, Recipient: R. Arnold, Marburg/Munich, Dedication: B. Wiedenmann, Berlin, 11:00-11:30 COFFEE BREAK 11:30-12:30 SESSION 3: Poorly Differentiated Endocrine Carcinomas Chairs: L. Kvols, Tampa, FL, ; P. Komminoth, Zürich, SUI 11:30-11:50 Diagnosis O. Nilsson, Gothenborg, 11:50-12:10 Therapy and Management (I): Surgery H. Ahlman, Gothenborg, 12:10-12:30 Therapy and Management (II): Medical Treatment J. Yao, Houston, TX, 12:30-14:00 LUNCH 14:00-15:15 SELECTED ABSTRACTS (II): Clinical Research Chairs: R. V. Thakker, Oxford, D. Ferone, Genoa, 14:00-14:15 Prevalence and features of MEN1 in a large cohort of gastroenteropancreatic and thoracic NET: data from a large multicentric Italian database P. Ferolla, Perugia, 14:15-14:30 Clinical results of PRRT with 90 Y-DOTATATE and 90 Y/ 177 Lu- DOTATATE - what is better for therapy? L. Krolicki, Warsaw, POL 14:30-14:45 Chemotherapy with 5-Fluorouracil, cisplatin and streptozocin (FCiSt) for neuroendocrine tumors T. Meyer, London, 14:45-15:00 Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group A. Rinke, Marburg, 15:00-15:15 First line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide J. Strosberg, Tampa, FL, 15:15-16:15 SESSION 4: Surgery, Established Techniques and Novel Approaches Chairs: R. Kianmanesh, Colombes, B. Eriksson, Uppsala, 15:15-15:35 Lung E. Lim, London, 15:35-15:55 Gut I. Modlin, New Haven, CT, 15:55-16:15 Pancreas A. Sauvanet, Clichy, 16:15-17:00 Poster Viewing 17:00 SATELLITE SYMPOSIA Session 3 Session 2 Abstracts 2 Session 4 6th Annual ENETS Conference 6 March 2009 5

C M Y CM MY CY CMY K SESSION PARTICIPANTS H. Ahlman, Gothenborg G. Åkerström, Gothenborg R. Arnold, Munich E. Baudin, Villejuif M. Caplin, London F. Costa, Sao Paulo W. de Herder, Rotterdam G. Delle Fave, Rome B. Eriksson, Uppsala D. Ferone, Genoa A. Grossman, London R. Jensen, Bethesda, MD G. Kaltsas, Athens R. Kianmanesh, Colombes P. Komminoth, Zürich B. Kos-Kud a, Zabrze M. Kulke, Boston, MA L. Kvols, Tampa, FL D. Kwekkeboom, Rotterdam E. Lim, London BRA NED GRE SUI POL NED C. Lombard-Bohas, Lyon M. Mallath, Mumbai I. Modlin, New Haven, CT O. Nilsson, Gothenborg K. Öberg, Uppsala D. O Toole, Dublin U.-F. Pape, Berlin U. Plöckinger, Berlin J. Ramage, Basingstoke G. Rindi, Parma P. Ruszniewski, Clichy H. Sasano, Sendai A. Sauvanet, Clichy T. Steinmüller, Berlin R. V. Thakker, Oxford E. Van Cutsem, Leuven D. R. Welch, Birmingham, AL B. Wiedenmann, Berlin J. Yao, Houston, TX IND IRL JAP BEL J. Ardill, Belfast A. Astudillo, Oviedo R. Bettini, Verona P. Brown, The Woodlands, TX ESP A. Couvelard, Clichy A. Kalhan, Cardiff L. Krolicki, Warsaw M. Mei, Beijing T. Meyer, London A. Rinke, Marburg J. Strosberg, Tampa, FL POL CHN ABSTRACT PRESENTERS A. Falchetti, Florence P. Ferolla, Perugia 6

ADVANCE REGISTRATION: Wednesday, 4 March 2009, 16:00 18:00 Conference participants can register the evening before the conference begins in the entrance lobby of the Granada Congress & Exhibition Centre. Thursday, 5 March 2009 11:00-13:00 REGISTRATION 13:00-13:20 Welcome and Introduction G. Rindi, ENETS Chairman, Parma, 13:20-14:30 SESSION 1: Standards of Care Chairs: U. Plöckinger, Berlin, A. Grossman, London, 13:20-13:35 Introduction U. Plöckinger, Berlin, 13:35-13:55 Diagnosis B. Eriksson, Uppsala, 13:55-14:15 Medical Therapy P. Ruszniewski, Clichy, 14:15-14:30 Surgical Therapy G. Åkerström, Gothenborg, 14:30-15:00 COFFEE BREAK 15:00-16:15 Selected Abstracts (I): Clinical Research Chairs: G. Kaltsas, Athens, GRE H. Sasano, Sendai, JAP 15:00-15:15 Assessment of the sensitivity of circulating neurokinin A and chromogranin A to changing prognosis in patients with serotoninproducing endocrine tumors of the ileum and colon J. Ardill, Belfast, 15:15-15:30 Snail as epithelial-mesenchymal transition marker in neuroendocrine tumors of the lung A. Astudillo, Oviedo, ESP 15:30-15:45 Non-functioning pancreatic endocrine tumors: Any correlation of tumor size with malignancy? R. Bettini, Verona, 15:45-16:00 LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome P. Brown, The Woodlands, TX, 16:00-16:15 Early identification of the MEN1-associated gastrinomas: Use of the secretin test in the experience of the Center for Hereditary Endocrine Tumors of Florence, Italy A. Falchetti, Florence, 16:15-17:15 Poster Viewing 17:15-18:15 ENETS General Assembly 18:15 WELCOME RECEPTION Session 1 Abstracts I 6th Annual ENETS Conference 5 March 2009 3